Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Current Leases (2019 - 2025)

Fate Therapeutics' Current Leases history spans 7 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Current Leases fell 38.48% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, down 38.48%, while the annual FY2025 figure was $4.6 million, 38.48% down from the prior year.
  • Current Leases reached $4.6 million in Q4 2025 per FATE's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $7.4 million in Q4 2024 to a low of $4.4 million in Q1 2021.
  • Average Current Leases over 5 years is $5.7 million, with a median of $5.7 million recorded in 2022.
  • Peak YoY movement for Current Leases: skyrocketed 132.46% in 2021, then tumbled 38.48% in 2025.
  • A 5-year view of Current Leases shows it stood at $5.6 million in 2021, then rose by 0.91% to $5.6 million in 2022, then grew by 9.74% to $6.2 million in 2023, then increased by 20.08% to $7.4 million in 2024, then crashed by 38.48% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Current Leases are $4.6 million (Q4 2025), $4.8 million (Q3 2025), and $5.7 million (Q2 2025).